The spectrum of pathogenic NF1 variants in participants enrolling on clinical trials of MEK inhibitors for plexiform neurofibroma.

Kotch C, Gomes A, Schatz KS, Dombi E, Brown S, Gross AM, Alves M, Perreault S, Mueller S, Reddy AT, Romo C, Bornhorst M, Tonsgard J, Weiss BD, Widemann B, Fisher MJ